Gene-editing technique to treat lung cancer is due to be tested in people in August
Chinese scientists are on the verge of being first in the world to inject people with cells modified using the CRISPR–Cas9 gene-editing technique.
A team led by Lu You, an oncologist at Sichuan University’s West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month. The clinical trial received ethical approval from the hospital’s review board on July 6.
“It’s an exciting step forward,” says Carl June, a clinical researcher in immunotherapy at the University of Pennsylvania in Philadelphia.
There have been a number of human clinical trials using an alternative gene-editing technique, including one led by June, that have helped patients combat HIV. June is also a scientific adviser on a planned US trial that would also use CRISPR–Cas9-modified cells for the treatment of cancer.
Last month, an advisory panel of the US National Institutes of Health (NIH) approved that project. But the trial also requires a green light from the US Food and Drug Administration (FDA) and a university review board. The US researchers have said they could start their clinical trial by the end of this year.
Ineffective chemo
The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed. “Treatment options are very limited,” says Lu. “This technique is of great promise in bringing benefits to patients, especially the cancer patients whom we treat every day.”
Learn more: Chinese Scientists to Pioneer First Human CRISPR Trial
The Latest on: CRISPR
[google_news title=”” keyword=”CRISPR” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR
- Can CRISPR help stop African Swine Fever?on April 26, 2024 at 5:00 pm
Vaccines based on weakened versions of viruses are often referred to as attenuated virus vaccines. “The CRISPR technology is quite easy to use, and therefore efficient, compared with traditional ...
- Experts develop way to harness CRISPR technology to deal with antimicrobial resistanceon April 26, 2024 at 3:10 pm
Antimicrobial resistance (AMR) is continuing to increase globally, with rates of AMR in most pathogens increasing and threatening a future in which every day medical procedures may no longer be ...
- CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Noteon April 26, 2024 at 2:50 pm
CRISPR Therapeutics AG (CRSP) closed the latest trading day at $53.91, indicating a +0.34% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 1.02%.
- Buy Rating on Crispr Therapeutics AG Backed by Exa-cel’s Precision and Favorable Safety Profileon April 25, 2024 at 11:24 pm
Salim Syed, an analyst from Mizuho Securities, maintained the Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The ...
- Researchers systematically investigate efficacy of CRISPR antimicrobial agentson April 25, 2024 at 1:28 pm
The antimicrobial potential of CRISPR-Cas systems is promising, yet how to best design or implement CRISPR nucleases remains poorly understood. An international team led by the Helmholtz Institute for ...
- This AI Just Designed a More Precise CRISPR Gene Editor for Human Cells From Scratchon April 25, 2024 at 1:25 pm
Based on large language models—the tech behind the popular ChatGPT—Profluent's AI designed a new gene editor and put it to work in human cells.
- Peninsula biotech co-founded by Jennifer Doudna lands CRISPR gene-editing pact with Regeneronon April 25, 2024 at 6:27 am
The big deal between Regeneron and a Peninsula biotech co-founded by Jennifer Doudna is also a small deal. And that’s a huge deal.
- Crispr Therapeutics: Now Is The Time To Buyon April 24, 2024 at 9:40 am
Despite recent FDA approvals for gene editing technology, CRISPR Therapeutics' stock declined. Click here to read an analysis of CRSP stock now.
- Enhanced CRISPR method enables stable insertion of large genes into the DNA of higher plantson April 24, 2024 at 8:46 am
Scientists at the Leibniz Institute of Plant Biochemistry (IPB) have succeeded for the first time in stably and precisely inserting large gene segments into the DNA of higher plants very efficiently.
- Profluent combines LLMs and CRISPR for open-source AI gene editing projecton April 23, 2024 at 11:00 am
Profluent has staked a claim at the intersection of some of the buzziest terms in biopharma. | Profluent has staked a claim at the intersection of some of the buzziest terms in biopharma. The protein ...
via Bing News